Akebia Therapeutics, Inc.
AKBA Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.66
KIRA · Stoqly’s AI analyst, in plain words
- Akebia Therapeutics, Inc. had $236M of revenue in fiscal 2025, up 47.5% on the year before. Over five years, revenue changed −4.3% a year on average.
- Its operating margin was 9.9%, up 41.5 pts: of every 100 in sales, about 10 is left after running the business.
- Akebia Therapeutics, Inc. lost $5.3M in fiscal 2025.
- Free cash flow was $67.7M in fiscal 2025, 28.7% of revenue.
- Akebia Therapeutics, Inc. has $137M more cash than debt.
Market cap
$178M
P/E
—
Revenue
$236M
Net income
−$5.3M
Free cash flow
$67.7M
Operating margin
9.9%
Akebia Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+47.5%
Yes. Sales grew 47.5% last year.
Does it make a profit?
−2.3%
No. It lost money last year.
Does profit turn into cash?
28.7%
Yes. 28.7% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Akebia Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Akebia Therapeutics, Inc.
- CIK
- 0001517022
Akebia Therapeutics, Inc. · AKBA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $212M | $292M | $195M | $160M | $236M |
| Revenue growth | −28.2% | 38.2% | −33.5% | −17.7% | 47.5% |
| Gross margin | 28.8% | 70.7% | 61.9% | 60.6% | 83.3% |
| Operating margin | −125.0% | −27.6% | −23.8% | −31.5% | 9.9% |
| Net income | −$282M | −$94.2M | −$51.9M | −$69.4M | −$5.3M |
| Net margin | −133.3% | −32.2% | −26.7% | −43.3% | −2.3% |
| Diluted EPS | −$1.70 | −$0.52 | −$0.28 | −$0.33 | −$0.02 |
| Cash | |||||
| Cash from operations | −$253M | −$73.2M | −$23.4M | −$40.7M | $68.0M |
| Capital expenditure | $0.1M | $0.1M | $0.0M | $0.0M | $0.3M |
| Free cash flow | −$253M | −$73.3M | −$23.4M | −$40.7M | $67.7M |
| FCF margin | −119.5% | −25.1% | −12.0% | −25.4% | 28.7% |
| Share count change | 19.9% | 10.1% | 2.6% | 12.5% | 21.9% |
| Debt and strength | |||||
| Cash and short-term investments | $150M | $90.5M | $42.9M | $51.9M | $185M |
| Debt incl. finance leases | $97.5M | $66.1M | $34.7M | $38.7M | $48.3M |
| Shareholders' equity | $74.0M | $5.2M | −$30.6M | −$49.2M | $32.6M |
| Net debt / EBITDA | — | — | — | — | −5.5x |
| Current ratio | 1.0x | 1.4x | 1.2x | 1.4x | 1.6x |
| Returns and quality | |||||
| Return on capital | −960.7% | — | — | — | — |
| Return on equity | −177.2% | −237.8% | — | — | — |
| Piotroski F-score | 3 | 5 | 3 | 2 | 6 |
| Altman Z'' | −12.1 | −14.7 | −22.6 | −25.5 | −12.5 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$1.0M
6 insiders
Of sales under plans
100%
$1.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Akebia Therapeutics, Inc. · AKBA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.66 a share, the company is worth $178M.
Source: SEC EDGAR XBRL filings (CIK 0001517022). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.